Table of Contents Author Guidelines Submit a Manuscript
Analytical Cellular Pathology
Volume 24, Issue 1, Pages 41-46

CD10 Expression in Non-Small Cell Lung Cancer

Glen Kristiansen, Karsten Schlüns, Yu Yongwei, Manfred Dietel, and Iver Petersen

Institute of Pathology, Charité University Hospital, 10117 Berlin, Germany

Received 18 January 2002; Accepted 12 March 2002

Copyright © 2002 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


CD10 is a cell surface endopeptidase that inactivates various potentially growth stimulatory peptides. In lung cancer cell lines this downregulation has been associated with increased proliferation. Downregulation of CD10 in lung cancer tissue is described, suggesting a potential role in carcinogenesis and a possible use of CD10 as a prognostic marker. We aimed to determine the rate of CD10 expression in our non‐small cell lung cancer (NSCLC) collection and to clarify its correlation with clinicopathological parameters and patient survival. 114 NSCLC were analysed immunohistochemically using a monoclonal CD10 antibody (clone NCL‐CD10‐270) on an NSCLC tissue micro array. The staining was semiquantitatively scored. CD10 expression was observed in 19% of cases, without any significant association with tumour type, ‐size, ‐grading, nodal status, clinical stage, and patient survival time. We conclude that a diagnostic use of CD10 immunostaining in NSCLC is unlikely.